Confirmatory Study of the Efficacy and Safety of the Fixed-dose Combination Atorvastatin / Fenofibrate Versus Atorvastatin on the Lipid Profile of Patients With Type 2 Diabetes (T2D) and Dyslipidaemia (DLP).

Phase IIIb, randomized, longitudinal, prospective, multicenter study to evaluate the efficacy and safety of the fixed-dose combination atorvastatin / fenofibrate versus atorvastatin on the lipid profile of patients with type 2 diabetes and dyslipidemia.

开始日期2022-02-15

申办/合作机构

Laboratorios Silanes SA de CV

NCT00664859 / Completed临床2/3期

A 12-Month, Open-Label, Extension Study of the Safety and Efficacy of LCP-AtorFen in Subjects With Dyslipidemia

The current study is designed to test the long-term (12-month) safety and efficacy of LCP-AtorFen, a combination of atorvastatin and fenofibrate, in patients with dyslipidemia

开始日期2007-10-01

申办/合作机构

Veloxis Pharmaceuticals A/S

NCT00504829 / Completed临床2期

A 12-Week, Multi-Center, Double-Blind, Randomized, Parallel-Group Study, Followed by a 12 Month Extension Study, of the Efficacy and Safety of LCP-AtorFen in Subjects With Dyslipidemia

The current study is designed to test the efficacy, safety and tolerability of LCP-AtorFen, a combination of atorvastatin and fenofibrate.

开始日期2007-07-01

申办/合作机构

Veloxis Pharmaceuticals A/S

100 项与阿托伐他汀钙/非诺贝特相关的临床结果

登录后查看更多信息

100 项与阿托伐他汀钙/非诺贝特相关的转化医学

登录后查看更多信息

100 项与阿托伐他汀钙/非诺贝特相关的专利（医药）

登录后查看更多信息

项与阿托伐他汀钙/非诺贝特相关的新闻（医药）

2007-11-20

·BioSpace

LifeCycle Pharma Completes Patient Enrollment in Phase II Clinical Trial of LCP-AtorFen for the Treatment of Mixed Dyslipidemia, Initiates 52-Week Open Label Extension Study

H0RSHOLM, Denmark--(BUSINESS WIRE)--LifeCycle Pharma A/S (OMX: LCP) (the “Company” or “LCP”), an emerging specialty pharmaceutical company, today announced that it has completed patient enrollment in its Phase II clinical trial of LCP-AtorFen for the treatment of mixed dyslipidemia, which commenced in July 2007 to compare LCP-AtorFen, the Company’s fixed-dose combination product candidate of atorvastatin and lowest dose fenofibrate, with Lipitor® (40 mg atorvastatin calcium tablets) and Tricor® (145mg fenofibrate tablets). In addition, the Company announced that it has initiated a 52-week, open-label extension study in order to capture additional safety and efficacy data on the use of LCP AtorFen in patients with mixed dyslipidemia.

合作

100 项与阿托伐他汀钙/非诺贝特相关的药物交易

登录后查看更多信息

外链

KEGG	Wiki	ATC	Drug Bank
-	-	-	DB05769

研发状态

10 条进展最快的记录,

后查看更多信息

适应症	最高研发状态	国家/地区	公司	日期
血脂障碍	临床3期	美国	Veloxis Pharmaceuticals A/S	2007-10-01

登录后查看更多信息

临床结果

适应症

分期

评价

查看全部结果

研究	分期	人群特征	评价人数	分组	结果	评价	发布日期


23-PUB (ADA2024)	临床3期	2型糖尿病 \| 血脂障碍	65	Atorvastatin/Fenofibrate 20 mg/160 mg	(繭襯製簾鏇鬱艱衊鹽獵) = 顧築繭範製簾廠窪鹽鹹夢憲鏇網獵製齋構獵艱 (膚築鏇製衊選憲鏇淵膚, 145.3)	积极	2024-06-14
				Atorvastatin 20 mg	(繭襯製簾鏇鬱艱衊鹽獵) = 艱壓淵鬱鏇齋糧夢網鹹夢憲鏇網獵製齋構獵艱 (膚築鏇製衊選憲鏇淵膚, 75.7)
NCT00664859 (CTgov)	临床2/3期	血脂障碍	140	LCP-AtorFen (LCP-AtorFen 40/100mg)	積願醖鹹遞繭構顧壓醖(積製憲範選糧選願範糧) = 淵鏇襯鑰鹹艱遞艱網範網鏇範膚獵衊願鹹遞糧 (積鏇膚襯願衊選鏇鹹齋, 壓鬱繭遞繭鏇顧鬱壓網 ~ 襯網獵積網餘壓衊範膚) 更多	-	2020-03-24
				Atorvastatin (Atorvastatin 40 mg)	積願醖鹹遞繭構顧壓醖(積製憲範選糧選願範糧) = 夢蓋構淵構襯膚蓋鬱鹹網鏇範膚獵衊願鹹遞糧 (積鏇膚襯願衊選鏇鹹齋, 淵齋鬱醖餘糧蓋糧窪鬱 ~ 艱築網廠壓繭齋範鬱繭) 更多
NCT00504829 (CTgov)	临床2期	血脂障碍	220	LCP-AtorFen (LCP-AtorFen 40/100mg)	艱淵憲餘廠憲窪艱鏇鬱(鹹積醖觸鹽淵遞簾網蓋) = 獵衊夢廠襯蓋觸襯餘壓獵網憲願膚糧夢遞顧鬱 (蓋淵鹽遞願製艱鹹網簾, 鹹簾淵顧淵蓋範願夢淵 ~ 遞積簾繭醖膚構衊鏇簾) 更多	-	2020-02-05
				Atorvastatin (Atorvastatin 40mg)	艱淵憲餘廠憲窪艱鏇鬱(鹹積醖觸鹽淵遞簾網蓋) = 齋憲選艱淵艱製鏇襯鑰獵網憲願膚糧夢遞顧鬱 (蓋淵鹽遞願製艱鹹網簾, 網襯憲艱襯膚襯糧鏇蓋 ~ 獵鏇範範壓構襯窪鏇蓋) 更多
NCT01974297 \| NCT00504829 (Pubmed \| Med Lett Drugs Ther)	临床2期	血脂障碍	220	Atorvastatin/fenofibrate FDC	膚顧網顧醖艱鹽壓鏇夢(築繭積膚繭遞壓齋憲鹹) = 構醖簾網艱艱鹹觸夢遞齋顧鬱齋範餘淵遞遞獵 (選衊築製選遞製鏇膚醖 ) 更多	-	2009-12-01
				Atorvastatin 40 mg	膚顧網顧醖艱鹽壓鏇夢(築繭積膚繭遞壓齋憲鹹) = 壓夢選願艱範夢構鑰製齋顧鬱齋範餘淵遞遞獵 (選衊築製選遞製鏇膚醖 ) 更多